Peptides DB
Research-centric peptide and protocol reference hub

HGH (Somatropin) record · updated 17h ago

Muscle & body compSkin & aestheticsGrade A · human clinicalResearch use only
All 68 studiesJump to the evidenceCompare
What is HGH (Somatropin) used for?

HGH (somatropin) is recombinant human growth hormone, FDA-approved for pediatric and adult GH deficiency and several wasting and short-stature conditions; widely studied for body composition off-label.

How it works: Stimulates IGF-1 production

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where HGH (Somatropin) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 146 registered trials. It describes the research record, not a recommendation.

Identity
NameHGH (Somatropin)
Chain length—
Molecular weight285.3 Da
FormulaC13H11N5O3
Structure typeSmall molecule
ClassHealing
Research levelFDA Approved
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 137552069. No verified residue count for this compound.

Pharmacology
MechanismStimulates IGF-1 production
RouteSubcutaneous injection
Half-life~20 min
Time to peak3–6 hours
DurationVariable
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 10, 2026. How this works →
Research stats
Total studies68
Human / animal / cellular49 / 3 / 1
Highest trial phasePhase 4
Years covered2020–2026
Latest study7d ago
Publication history
20202026
Research funding
209 NIH projects · $22.8M awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports6
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

68 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Advances in Systemic Treatment of Breast Cancer.
TakeawayNot reported in abstract.
review2026Title only0.10
Converging Growth Trajectories During Recombinant Human Growth Hormone Therapy in Children With Isolated and Combined Pituitary Hormone Deficiency.
FindingCumulative height SDS gains after 48 months: 3.10 ± 1.36 for CPHD vs. 1.92 ± 0.87 for IGHD, p < 0.001.
Human2023Full text read0.90
Microstructural Vulnerability of the Tibial Tubercle Apophysis During Growth Hormone Therapy: A Multicenter Prospective Cohort Study Using Diffusion Tensor Imaging-MRI.
FindingADC was significantly higher at 8 months compared with baseline (1.61 × 10-3 vs 1.52 × 10-3 mm2/sec, p = 0.041).
Human2023Full text read0.80
A Novel ACAN Missense Variant in the G1 Domain Causes Short Stature, Advanced Bone Age, and Osteochondritis Dissecans: A Case Report and Literature Review.
FindingNot reported in abstract.
Human2023Full text read0.80
Interaction between vitamin D and the growth hormone/insulin-like growth factor 1 axis in children: a systematic review and meta-analysis.
FindingWMD: 5.83 ng/mL increase in vitamin D levels after rhGH treatment, 95% CI: 3.72 to 7.94, p<0.00001.
review2026Full text read0.80
Interaction between vitamin D and the growth hormone/insulin-like growth factor 1 axis in children: a systematic review and meta-analysis.
FindingWMD: 5.83 ng/mL increase in vitamin D levels after rhGH treatment, 95% CI: 3.72 to 7.94, p<0.00001.
review2026Full text read0.80
A Novel ACAN Missense Variant in the G1 Domain Causes Short Stature, Advanced Bone Age, and Osteochondritis Dissecans: A Case Report and Literature Review.
FindingNot reported in abstract.
Human2026Full text read0.80
Mosaic Trisomy 14 with Severe Short Stature: A Case Report.
FindingHeight increased by 1.9 cm after three months.
Human2023Full text read0.80
Circulating Asprosin Declines During 24 Months of Growth Hormone Replacement and Is Associated with IGF-1 and Metabolic Remodeling in Adults with Growth Hormone Deficiency.
FindingNot reported in abstract.
Human2023Full text read0.80
Converging Growth Trajectories During Recombinant Human Growth Hormone Therapy in Children With Isolated and Combined Pituitary Hormone Deficiency.
FindingCumulative height SDS gains after 48 months: CPHD 3.10 ± 1.36 vs IGHD 1.92 ± 0.87; p < 0.001.
Human2026Full text read0.80
Clinical characteristics and growth hormone treatment response in children with borderline versus lower peak growth hormone stimulation test responses.
FindingGroup 1 had higher BMI (median 16.1 vs 15.0 kg/m², P < 0.001)
Human2026Full text read0.80
Immunogenicity Profile of Lonapegsomatropin During Long-Term Treatment in Children With Growth Hormone Deficiency.
Finding4.7% of treated children developed anti-lonapegsomatropin antibodies.
Human2023Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching HGH (Somatropin) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much HGH (Somatropin) is discussed should be drawn from it.

Articles mentioning HGH (Somatropin)